United States

People: INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

26 May 2017
Change (% chg)

$-0.08 (-0.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Babich, Michael 

Mr. Michael L. Babich is Director of the Company. He was President, Chief Executive Officer of Insys Therapeutics Inc. Michael Babich has served as our President since November 2010 and was appointed as our Chief Executive Officer in March 2011. Mr. Babich has also served on our Board since 2008. From March 2007 until November 2010, Mr. Babich served as the Chief Operating Officer and a director of Insys Pharma, our wholly-owned subsidiary, which was responsible for the initial development of Dronabinol SG Capsule and many of our product candidates, including Subsys and our other dronabinol product candidates. Prior to that, from 2001 to 2007, Mr. Babich worked at EJ Financial Enterprises, a venture capital firm specializing in early stage and startup investments primarily in the healthcare sector. During his time at EJ Financial Enterprises, Mr. Babich held various roles and worked on various projects, including private equity transactions, asset management and strategic consulting for both public and private companies. Prior to his work at EJ Financial Enterprises, Mr. Babich worked at the Northern Trust Corporation managing mid- to large-cap portfolios for high net worth individuals. Mr. Babich also has served as a director and in management roles at Alliant Pharmaceuticals. Mr. Babich received an MBA from the Kellogg School of Management at Northwestern University and a B.A. from the University of Illinois at Urbana-Champaign. We believe that Mr. Babich’s business expertise, including his experience working with the investment community, provides him the operational expertise, breadth of knowledge and valuable understanding of our industry to qualify him to serve on our board of directors and as our President and Chief Executive Officer.

Basic Compensation

Total Annual Compensation, USD 889,229
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,650,680
Fiscal Year Total, USD 2,539,910

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Steven Meyer


Saeed Motahari


Darryl Baker


Franc Fosse


Michael Babich


John Kapoor

As Of  30 Dec 2014